Today, President Donald J. Trump announced the 17th agreement with a major pharmaceutical manufacturer, Regeneron, to lower prescription drug prices that Americans pay for some of the world’s most ...

The final major drugmaker President Donald Trump had pressed to accept a most-favored-nation deal has signed an agreement ...

The administration Apri 23 reached a most-favored-nation drug pricing agreement with Regeneron, the maker of the popular cholesterol medicine Praluent. This is the 17th such agreement by a drug ...

Most Favored Nation (MFN) drug pricing is just price controls by another name. Instead of openly capping what a drug can cost ...

Regeneron will cut the price of its cholesterol-lowering treatment Praluent to $225, down from $537, on the TrumpRx website.

President Donald Trump has announced an MFN pricing deal with Regeneron to lower prescription drug prices that Americans pay for some of the world's most innovative drugs ...

The government has revised the rules for implementing the minimum access volume (MAV) mechanism, citing the need for ...

With Regeneron poised to announce a drug pricing deal with the White House Thursday, all 17 companies targeted in a round of ...

ADVI’s head of market access policy strategy discusses how the Trump administration’s efforts. With the launch of TrumpRx earlier this year, Americans got their first taste of how the administration ...

When the Trump administration announced its Most Favored Nation policy, it was portrayed as a simple, sensible idea. Drug ...

In a world where pricing decisions are increasingly interconnected, a risk for healthcare leaders to consider is lagging evidence.​ ...

MFN policies are likely to impact more than pricing, and drug companies may alter drug launch plans in the future. With the launch of TrumpRx earlier this year, Americans got their first taste of how ...